



CONFIDENTIAL

CANCER FUND I

INVEST **BEYOND RESEARCH**



CANCER FUND

BEYOND RESEARCH

Impact-focused venture firm supported by a community of survivors, patients, experts, and investors seeking a meaningful impact on cancer and return potential.

Impact Focus

Patient Outcomes

Improving survivability and quality of life

Access to Care

Increasing care access to underserved and at-risk individuals

Cost of Care

Reducing cost-barriers to patients and healthcare institutions

General Investment Themes



Therapies & Management



Diagnostics & Monitoring



Preventions & Enabling Technologies

INVESTING: THE NEW WAY TO FIGHT CANCER

Despite billions in **cancer research funding**, the fight rages on.

We need a better approach:


1. The Funding Gap BEYOND RESEARCH is ***the Problem***
1. Investing is ***a Solution*** with impact but inaccessible for many.

CANCER FUND makes impact investing easy

THE *FUNDING GAP* IS REAL

The BEYOND RESEARCH Funding Gap

600+ Companies Seeking ~\$4B in Pre-Seed, Seed, Seed+ and Series A Funding



2021 Investment in Life Sciences by Round, Source: CB Insights, Life Sciences Investments, 2021

| | | | | | | | |
|--|--|------------|--|----------|---|----------|----------|
| Research Funding (NCI / Grants) | Pre-Seed | Seed/Seed+ | Series A | Series B | Series C | Series D | Series E |
| RESEARCH PHASE: Foundational Research, Discovery | INNOVATION PHASE: Company Formation, Team Recruitment, Discovery and Screening | | CLINICAL PHASE: Phase I Trials, Phase 2 Trials, Phase 3 Trials | | APPROVAL PHASE: FDA Review, New Drug Application, Labelling Review, Facility Inspection | | |

INVESTING IS A SOLUTION


Driving innovations from 0 to 1...

Getting to 'First in Man' is a critical milestone for innovations on the long road to patients.

CANCER FUND I invests in

Promising early-stage cancer innovators

Companies targeting First in Man within 0 to 36 months.



Seed, Seed +, Series A and Series B opportunities

WE INVEST TO IMPACT LIVES

To benefit our PRIMARY STAKEHOLDERS:



Patients & Survivors

IMPACT GOALS

- Improve Patient Outcomes
- Increase Access to Care
- Reduce Cost of Care

IMPACT OBJECTIVES (to be defined for each investment)


- Increase Survivorship by ___%
- Reduce Incidence of Mortality by ___%
- Increase Access to Care by ___%
- Reduce Cost of Care by ___%

IMPACT METRICS*

- Additional Months of Survivorship
- Reduced Mortality
- Total Population w/ Access
- Total Population Affordability

*see CANCER FUND Impact Measurement, Tracking, and Reporting Methodology for addition information.

Secondary Stakeholders:



At Risk Populations

REDUCE INCIDENCE

- Preventative Solutions
- Earlier Access to Care
- Wellness Enablement



Medical Pros & Caregivers

IMPROVE CARE DELIVERY

- Better Patient Outcomes
- Higher Patient Satisfaction
- Increase Capacity




Payers & Policy Makers

OPTIMIZE ADMINISTRATION

- Faster Response
- Lower Cost of Care
- Broader Coverage

WE INVEST ACROSS CANCER TYPES

We target a range of **CANCERS**:



* Projections are for illustration purposes only; actual investments will vary

WE BRING INNOVATIONS CLOSER TO PATIENTS

We focus on three innovation THEMES:



Preventions & Enabling Technologies

Predictive Analytics

Behavioral Risk Assessment

Hereditary Screening



Diagnostics & Monitoring

AI / ML Enabled Diagnostics

Metabolic Sensing

Next-Gen Sequencing



Therapies & Management

Gene Therapies

Epigenetic Medicines

Computable Phenotypes

EXAMPLES

WE INVEST IN EARLY-STAGE COMPANIES

We invest early, add value, and plan Series ABCD follow-on investments

INVESTMENT STAGES

PRE-SEED

SEED

SEED+

SERIES A

SERIES B,C,D



PLANNED INVESTMENTS

NUMBER OF INVESTMENTS

11

8

6

6

9

INVESTMENT ALLOCATION

6%

10%

10%


21%

53%






We manage risk through a diversified portfolio

* Projections are for illustration purposes only; actual returns will vary and could result in a total loss of principal.

OUR PORTFOLIO EVALUATION PROCESS



CANCER FUND I: INVESTMENT PLAN (%)

| | | YEAR 1 | YEAR 2 | YEAR 3 | YEAR 4 | YEAR 5 | YEAR 6 | YEAR 7 | YEAR 8 | TOTAL |
|---|--------|--------|--------|--------|--------|--------|--------|--------|--------|-------|
| Net Investable Capital | | 4% | 9% | 19% | 11% | 11% | 18% | 11% | 10% | 8% |
| Pre Seed  | Number | 2 | 3 | 4 | 2 | | | | | 11 |
| | Amount | 2% | 2% | 1% | 1% | | | | | 6% |
| Seed  | Number | 2 | 2 | 2 | 2 | | | | | 8 |
| | Amount | 2% | 2% | 4% | 2% | | | | | 10% |
| Seed +  | Number | | 1 | 2 | 2 | 1 | | | | 8 |
| | Amount | | 2% | 4% | 3% | 1% | | | | 9% |
| Series A  | Number | | 1 | 1 | 2 | 1 | 1 | | | 8 |
| | Amount | | 3% | 10% | 5% | 2% | 1% | | | 21% |
| Series B, C, D  | Number | | | | 2 | 2 | 2 | 2 | 1 | 9 |
| | Amount | | | | 11% | 15% | 10% | 10% | 8% | 54% |
| Total | Number | 4 | 7 | 9 | 10 | 4 | 3 | 2 | 1 | 40 |
| | Amount | 4% | 9% | 19% | 22% | 18% | 11% | 10% | 8% | 100% |

Offering 1

Offering 2

* Projections are for illustration purposes only; actual returns will vary and could result in a total loss of principal.

CANCER FUND I: PROJECTED PERFORMANCE

A SUSTAINABLE model to drive cancer innovation.

| RETURNS | SCENARIO A (TOTAL LOSS) | SCENARIO B (POSITIVE) | SCENARIO C (TARGET) | SCENARIO D (OPTIMISTIC) |
|--------------------------------------|----------------------------|--------------------------|------------------------|----------------------------|
| Number of Exits | 0 | 3 | 5 | 7 |
| Distribution Targets | \$0 | \$36.5MM | \$78MM | \$122MM |
| Annualized (ROI) | -100% | 2% | 10% | 15% |
| Return on Investment / (Multiple) | -100% | 22% / 1.2x | 160% / 2.5x | 300% / 4x |

* Projections are for illustration purposes only; actual returns will vary and could result in a total loss of principal.



Portfolio Investment Summary

Reglagene Series A (Feb 2021)

Contact Info:
Address: 1703 E. Mabel St., Tucson, AZ, 85721
Phone: (520) – 235 - 0365
Email: Austin@reglagene.com
Website: www.reglagene.com

Financial Information:
 Stage: Seed Fund
 Pre-valuation: \$4.75M
 Capital Raising: \$2M
 Round closed: December 31, 2020

CF Deal:
 CONFIDENTIAL

Use of Funds:

1. Complete Animal Trials
2. Deliver Version 2 Medicines
3. Pre-clinical Development of 2 cancer medicines

Management Team:
CEO: Richard Austin, PhD, MBA
CSO: Laurence Hurley, PhD
CFO: Betty Weaver, CPA
BD Manager: Michael Abrahamson, PharmD

| |
|--|
| Executive Summary: Reglagene’s breakthrough is the creation and development of orally administered medicines that regain control of genes exploited by disease |
| Problem: When confronted with an effective therapy, cancer itself enters a fight for its life. To defeat the therapy, cancer will make genetic changes to its own DNA blueprint. Like evolution on the micro scale, cancer selects for genetic changes that negate the effect of the therapy while sparing the cancer cells themselves |
| Business Model: As a pharmaceutical development company, Reglagene’s revenues are derived from licensing or selling its core therapeutic assets, typically to large enterprise pharmaceutical companies that are dependent on external innovation to drive future revenue and earnings. |
| Market/Competition: Reglagene’s planned beachhead market is the prostate cancer therapeutic market with 200,000 new cases annually. From a technology perspective, Reglagene’s nearest competition comes from other companies in the epigenetic therapy space and indirectly from gene modification approaches like Omega Therapeutics, Constellation Pharmaceutical and Foghorn Therapeutics. |
| Competitive Advantage: Reglagene is the only company we are aware of that uses oral epigenetic medicines that leverage small molecule approaches to target specific cancer genes. It is also the only company exploiting quadruplexes as the “lever” to exercise control of gene expression. |
| Exit: Our analysis suggests, based on the current \$4.5M valuation, a deal value comparable to \$650M could be possible in 3-4 years, though more likely in 5-7 years. Based on these assumptions, a projected return could be in the range of 5x to 15x. |

Capital Raised in Round:

Non-Dilutive Funding:
 National Cancer Institute
 National Institute of Neurological Disorders and Stroke
 Arizona Commerce Authority
 Flinn Foundation
 US Small Business Administration

Investors in Round:
 Desert Angels
 VIVA BioInnovator



Portfolio Investment Summary

Reglagene Series A-1 (Feb 2023)

Contact Info:

Address: 3320 N Campbell Ave
Suite 200, Tucson, AZ 85719

Phone: (520) – 235 - 0365

Email: Austin@reglagene.com

Website: www.reglagene.com

Financial Information:

CONFIDENTIAL

CF Deal:

CONFIDENTIAL

Use of Funds:

1. Lead Program through Phase I
2. Backup Series through Validation
3. Platform expansion

Management Team:

CEO: Richard Austin, PhD, MBA

CSO: Laurence Hurley, PhD

CFO: Betty Weaver, CPA

BD Manager: Michael

Abrahamson, PharmD

Executive Summary:

Reglagene's breakthrough medicine has continued to exhibit a competitive advantage over traditional therapies due to its low toxicity and ability to be administered orally.

Problem:

Competitor drugs currently contain high toxicity profiles and a host of unpleasant side effects for patients. Unfortunately, little to no innovation has occurred in decades, leaving GBM patients with limited options and low survival rates.

Business Model:

As a pharmaceutical development company, Reglagene's revenues will be derived from licensing or selling its core therapeutic assets, typically to large enterprise pharmaceutical companies that are dependent on external innovation to drive future revenue and earnings.

Market/Competition:

In late 2021, Reglagene pivoted their beachhead market from prostate cancer to Glioblastoma. The pivot was based on excellent blood brain barrier (BBB) penetration in the industry-standard rodent model that correlates with human brain penetration. Study data also indicated significantly lower toxicity levels when compared to current chemotherapy and radiation therapy regimens, indicating potential to improve patient survivorship in aggressive Stage 4 cancers.

Competitive Advantage:

Reglagene has relatively low toxicity when compared to typical chemotherapies and can be administered orally. Due to its low toxicity, it can be administered in high concentration doses of 100mg/kg, which is less than half the dose needed to produce toxic side effects.

Exit:

Based on the \$40mm post money valuation of their current round, we are targeting an approximate valuation of \$700mm in a Series C within 2-4 years.

CANCER FUND I

INVEST **BEYOND RESEARCH**

JOIN US.

*Unlike donating to charity,
CANCER FUND I investors share in our profits.*

CONTACT

Anthony Bajoras
Managing Director

CANCER FUND

anthony@cancerfund.com
602-821-1500

DISCLAIMERS & FORWARD LOOKING STATEMENTS

Disclaimers: Contents of this document are provided for general information purposes only and do not constitute an offer to sell or a solicitation of an offer to buy any security of CANCER FUND or its affiliates in any jurisdiction. CANCER FUND does not intend to solicit and IS not soliciting, any action with respect to any Security or any other contractual relationship. Nothing in this presentation or the contents thereof, individually or taken in the aggregate, constitutes an offer of securities for sale or a solicitation of an offer to buy any security in the United States or in any other jurisdiction in which such an offer or solicitation is unlawful. CANCER FUND does not make investment recommendations and no communication, through this document or in any other information materials should be construed as a recommendation for any security. Cancer Fund I, LLC and CF1 Reglagene Partners, LLC offer their investments through [Funds411.com](https://www.funds411.com) a “funding portal” as defined in section 3(a)(80) of the Securities Exchange Act of 1934 and under Rule 506(c) issued by the Securities and Exchange Commission (SEC) and those investments are offered to accredited investors only. Investments in early-stage ventures are speculative in nature and involve a high degree of risk. Those investors who cannot afford to lose their entire investment should not invest in such projects. There is no guarantee that the stated project valuation and other terms are accurate or in agreement with the market or industry valuations. Additionally, investors may receive restricted ownership that may be subject to holding period requirements. Early-stage investments should only be part of your overall private investment portfolio. Investors who cannot hold an investment for at least 5 years should not invest.

Forward Looking Statements: When used herein, the words “anticipate”, “believe”, “could”, “estimate”, “expect”, “going forward”, “intend”, “may”, “ought to”, “plan”, “project”, “seek”, “should”, “will”, “would” and similar expressions, as they relate to CANCER FUND, CANCER FUND affiliates including CANCER FUND I, LLC, CF1 Reglagene Partners, LLC and CANCER FUND’s management, or any of their actual or prospective investments, are intended to identify forward-looking statements. These forward-looking statements reflect CANCER FUND’s views at the time such statements were made with respect to future events and are not a guarantee of future performance or developments. You are strongly cautioned that reliance on any forward-looking statements involves known, unknown, and unknowable risks and uncertainties. Actual results and events may differ materially from information contained in the forward-looking statements as a result of a number of factors, including any changes in the laws, rules and regulations relating to any aspects of CANCER FUND’s or its affiliates business operations, general economic, market and business conditions, including capital market developments, changes or volatility in interest rates, foreign exchange rates, equity prices or other rates or prices, various business opportunities that CANCER FUND may or may not pursue, changes in population growth and other demographic trends, including mortality, morbidity and longevity rates, persistency levels, CANCER FUND’s ability to identify, measure, monitor and control risks in CANCER FUND’s business, including its ability to manage and adapt its overall risk profile and risk management practices, and seasonal fluctuations and factors beyond CANCER FUND’s control. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. CANCER FUND undertakes no obligation to publicly update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise.